Compare Icl Group Ltd (ICL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs BIO-TECHNE Corp — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and BIO-TECHNE Corp for 64 Days on average.
| ICL | TECH | |
|---|---|---|
Market Cap | $6.47B | $11.36B |
Volume | 1,387,140 | 5,390,331 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $72.61 |
52-Week Low | $4.80 | $43.31 |
Typical Hold Time | 56 Days | 64 Days |
Enterprise Value | $9.11B | $11.39B |
Dividend Yield | 4.11% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 1.57% on the day. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 earnings of $0.12 per share, beating estimates, but revenue and net income margins have declined from prior years. Valuation ratios like P/E of 20.83 and P/S of 0.84 suggest moderate pricing relative to earnings and sales. A dividend of $0.06 is scheduled for payment in September 2026.
The outlook is mixed. Positive earnings beats and a low EV/EBITDA of 6.68 indicate potential value, but bearish technicals and declining profitability pose risks. Analyst consensus is neutral with a $6.08 price target, implying upside. Key risks include industry headwinds like higher input costs and competitive pressures.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
